$29.33
1.28%
Nasdaq, Aug 29, 11:01 pm CET
ISIN
US88322Q1085
Symbol
TGTX

TG Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET
Neutral
The Motley Fool
29 days ago
TG Therapeutics Q2 Revenue Up 91%
Negative
Investors Business Daily
29 days ago
TG Therapeutics stock crashed Monday after the drugmaker reported in-line sales of Briumvi, but missed second-quarter profit expectations.
Neutral
Seeking Alpha
29 days ago
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Adam Waldman - Chief Commercialization Officer Jenna Bosco - Senior Vice President of Corporate Communications Michael S. Weiss - Chairman, CEO & President Sean A.
Neutral
GlobeNewsWire
29 days ago
Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million Raises full year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million Conference call to be held today, Monday, August 4, 2025, at 8:30 AM ET    NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today annou...
Neutral
GlobeNewsWire
about one month ago
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 4, 2025, at 8:30 AM ET to discuss results for the second quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S.
Positive
Seeking Alpha
2 months ago
TG Therapeutics, Inc.'s BRIUMVI saw Q1 2025 revenue surge 137% YoY to $119.7M, driven by strong U.S. growth. A subcutaneous version of TGTX's BRIUMVI is in phase 1 trials, with late-stage development planned for 2025, aiming to broaden patient reach and administration options. Azer-cel, an allogeneic off-the-shelf CD19 CAR-T, is in phase 1 for progressive MS, targeting a new MS market segment b...
Neutral
GlobeNewsWire
3 months ago
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, being held in Miami, FL on June 9-11, 2025.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today